The Leading Reasons Why People Are Successful At The Personalized Depression Treatment Industry > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapy and medication are not effective for a lot of people who are depressed. The individual approach to treatment could be the solution.

Cue is an intervention platform that converts sensors that are passively gathered from smartphones into customized micro-interventions that improve mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to discover their feature predictors and reveal distinct characteristics that can be used to predict changes in mood as time passes.

Predictors of Mood

Depression is one of the most prevalent causes of mental illness.1 Yet, only half of those who have the condition receive treatment1. To improve outcomes, clinicians must be able to recognize and treat patients most likely to respond to specific treatments.

A customized depression treatment plan can aid. Using mobile phone sensors as well as an artificial intelligence voice assistant and other digital tools, researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from which treatments. Two grants totaling more than $10 million will be used to identify biological and behavioral indicators of response.

The majority of research on predictors for depression treatment effectiveness has been focused on clinical and sociodemographic characteristics. These include demographic variables like age, sex and education, clinical characteristics such as symptom severity and comorbidities, and biological markers like neuroimaging and genetic variation.

While many of these factors can be predicted by the data in medical records, only a few studies have utilized longitudinal data to explore predictors of mood in individuals. A few studies also consider the fact that mood can be very different between individuals. Therefore, it is crucial to develop methods which allow for the analysis and measurement of individual differences between mood predictors treatments, mood predictors, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to detect patterns of behaviour and emotions that are unique to each person.

The team also developed a machine-learning algorithm that can create dynamic predictors for each person's mood for depression. The algorithm combines these individual variations into a distinct "digital phenotype" for each participant.

This digital phenotype was associated with CAT DI scores which is a psychometrically validated symptom severity scale. However the correlation was not strong (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 1003) and varied widely among individuals.

Predictors of Symptoms

Depression is one of the most prevalent causes of disability1 but is often untreated and not diagnosed. In addition, a lack of effective treatments and stigma associated with depressive disorders stop many from seeking treatment.

To aid in the development of a personalized treatment plan to improve treatment, identifying the predictors of symptoms is important. However, the current methods for predicting symptoms are based on the clinical interview, which is unreliable and only detects a small number of features related to bipolar depression treatment.2

Using machine learning to combine continuous digital behavioral phenotypes captured through smartphone sensors and a validated online tracker of mental health (the Computerized Adaptive Testing Depression Inventory CAT-DI) with other predictors of severity of symptoms can improve diagnostic accuracy and increase the effectiveness of treatment for depression. These digital phenotypes provide a wide range of unique behaviors and activities that are difficult to record through interviews and permit continuous and high-resolution measurements.

The study included University of California Los Angeles (UCLA) students who were suffering from mild to severe depressive symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 that was created under the UCLA Depression Grand Challenge. Participants were referred to online support or in-person clinical treatment in accordance with their severity of depression. Those with a score on the CAT-DI of 35 65 were assigned online support with the help of a coach. Those with a score 75 were routed to clinics in-person for psychotherapy.

Participants were asked a series of questions at the beginning of the study regarding their psychosocial and demographic characteristics as well as their socioeconomic status. These included sex, age, education, work, and financial status; if they were partnered, divorced or single; the frequency of suicidal thoughts, intentions or attempts; and the frequency with the frequency they consumed alcohol. The CAT-DI was used to assess the severity of depression symptoms on a scale from 100 to. The CAT-DI test was conducted every two weeks for those who received online support, and weekly for those who received in-person assistance.

Predictors of the Reaction to Treatment

Research is focusing on personalized treatment for depression. Many studies are aimed at identifying predictors, which will help clinicians identify the most effective drugs to treat each individual. Pharmacogenetics, in particular, uncovers genetic variations that affect how the body's metabolism reacts to drugs. This lets doctors select the medication that will likely work best drug to treat anxiety and depression for each patient, reducing the time and effort needed for trial-and error treatments and avoid any negative side effects.

Another approach that is promising is to build models for prediction using multiple data sources, including data from clinical studies and neural imaging data. These models can be used to determine which variables are the most predictive of a particular outcome, like whether a medication will help with symptoms or mood. These models can also be used to predict the response of a patient to treatment that is already in place and help doctors maximize the effectiveness of their current treatment.

A new generation uses machine learning techniques such as the supervised and classification algorithms such as regularized logistic regression, and tree-based techniques to combine the effects of multiple variables and increase the accuracy of predictions. These models have shown to be useful in forecasting treatment outcomes, such as the response to antidepressants. These approaches are gaining popularity in psychiatry, and it is likely that they will become the standard for the future of clinical practice.

The study of depression treatments's underlying mechanisms continues, as do ML-based predictive models. Recent research suggests that depression is connected to the dysfunctions of specific neural networks. This suggests that an individualized treatment for depression will be based upon targeted therapies that restore normal function to these circuits.

One method of doing this is to use internet-based interventions that can provide a more individualized and personalized experience for patients. A study showed that an internet-based program improved symptoms and provided a better quality of life for MDD patients. Additionally, a randomized controlled study of a personalised treatment for depression demonstrated an improvement in symptoms and fewer adverse effects in a significant number of participants.

Predictors of side effects

In the treatment of depression one of the most difficult aspects is predicting and identifying the antidepressant that will cause very little or no adverse negative effects. Many patients are prescribed a variety drugs before they find a drug that is both effective and well-tolerated. Pharmacogenetics offers a fresh and exciting way to select antidepressant medicines that are more effective and precise.

Many predictors can be used to determine which antidepressant to prescribe, such as gene variants, patient phenotypes (e.g., sex or ethnicity) and comorbidities. However, identifying the most reliable and valid predictive factors for a specific treatment will probably require controlled, randomized trials with significantly larger numbers of participants than those typically enrolled in clinical trials. This is due to the fact that the identification of interactions or moderators may be much more difficult in trials that take into account a single episode of treatment per participant instead of multiple episodes of treatment over a period of time.

In addition, predicting a patient's response will likely require information on the severity of symptoms, comorbidities and the patient's subjective perception of the effectiveness and tolerability. Presently, only a handful of easily assessable sociodemographic and clinical variables seem to be correlated with response to MDD, such as gender, age race/ethnicity, SES, BMI, the presence of alexithymia and the severity of depression symptoms.

Many challenges remain in the application of pharmacogenetics to treat depression. First it is necessary to have a clear understanding of the genetic mechanisms is essential as well as an understanding of what constitutes a reliable predictor for treatment response. Ethics, such as privacy, and the ethical use of genetic information are also important to consider. Pharmacogenetics can be able to, over the long term reduce stigma associated with mental health treatments and improve the outcomes of treatment. But, like any other psychiatric treatment, careful consideration and planning is essential. At present, it's recommended to provide patients with various depression medications that are effective and encourage them to talk openly with their physicians.